Welcome to the CJU website » LOG IN


Ileal perforation in the setting of atezolizumab immunotherapy for advanced bladder cancer
Department of Urology, University of Virginia, Charlottesville, Virginia, USA
Oct  2018 (Vol.  25, Issue  5, Pages( 9525 - 9526)
PMID: 30281011


Text-Size + 

  • Atezolizumab is a promising immunotherapy for advanced urothelial carcinoma. Like other immune checkpoint inhibitors, it can produce rare immune-related adverse events (IRAEs). Here we present the recent case of a patient with metastatic bladder cancer who developed diarrhea and abdominal pain months after beginning atezolizumab therapy. He presented to our institution with an ileal perforation secondary to atezolizumab-induced enterocolitis. After surgical repair, the patient's condition improved, and he was discharged. We discuss the management of atezolizumab-induced enterocolitis, including the importance of early recognition and intervention to prevent more devastating complications.